CHM
Chimeric Therapeutics Limited
🇦🇺 ASX
🧬 BIOTECHNOLOGY
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-25.07%
Annual Growth
4 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
5
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Chimeric Therapeutics Ltd. is a clinical stage cell therapy company, which engages in the development and commercialization of cell therapies in oncology. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-01-18. The firm is focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its pipeline includes CHM 1101 and CHM 2101. Its CHM 1101 (CLTX CAR-T) is a CAR-T therapy developed for the treatment of patients with solid tumors. CHM-1101 is being studied in a Phase 1B clinical trial in recurrent/ progressive glioblastoma. CHM 2101 is a third generation CDH17 CAR T, which is in preclinical development with a planned Phase I clinical trial in neuroendocrine tumors, colorectal, pancreatic and gastric cancer. Its pipeline also includes the CORE-NK platform, a clinically validated, off-the-shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). The firm is also focused on the development of NK and CAR NK assets with plans for Phase 1B clinical trials in solid tumors and blood cancers.
📈 Performance
Price History
-97.89%
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.01
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in CHM
5
📊 Total Capital Earnings
$51K
🔃 Average investment frequency
34 weeks
💵 Average investment amount
$3,960
⏰ Last time a customer invested in CHM
51 days
CHM investor breakdown
💵 Income of investors
More than 200k
20%
150k - 200k
100k - 150k
50k - 100k
20%
Less than 50k
20%
👶 Age of investors
18 - 25
26 - 34
20%
35 - 90
80%
🙋 Legal gender of investors
Female
20%
Male
80%
Pearlers who invest in CHM also invest in...
Chimeric Therapeutics Ltd. develops Chlorotixin CAR-T technology based cell therapies for the curation of solid tumors. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-01-18. The firm is focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its pipeline includes CHM 1101 and CHM 2101. Its CHM 1101 (CLTX CAR-T) is a CAR-T therapy developed for the treatment of patients with solid tumors. CHM-1101 is being studied in a Phase I clinical trial in recurrent/ progressive glioblastoma. CHM 2101 is a third generation CDH17 CAR T, which is in preclinical development with a planned Phase I clinical trial in neuroendocrine tumors, colorectal, pancreatic and gastric cancer. Its pipeline also includes the CORE-NK platform, a clinically validated, off-the-shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). The firm is also focused on the development of four NK and CAR NK assets with plans for Phase I clinical trials in solid tumors and blood cancers.
🧬 BIOTECHNOLOGY
IMU
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
🙌 Performance (5Yr p.a)
7.86%
📊 Share price
$0.04 AUD
🧬 BIOTECHNOLOGY
IVV
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
20.94%
📊 Share price
$63.52 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
VAE.AX was created on 2015-12-09 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard FTSE Asia ex Japan Shares Index ETF seeks to track the return of the FTSE Asia Pacific ex Japan, Australia and New Zealand Index (with net dividends reinvested) in Australian dollars, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.04%
📊 Share price
$80.10 AUD
⛳️ DIVERSIFIED
🤖 TECHNOLOGY
🌏 GLOBAL
ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).
🙌 Performance (5Yr p.a)
13.06%
📊 Share price
$85.62 AUD
🌏 GLOBAL
🛍️ CONSUMER
📈 HIGH PRICE GROWTH
🏭 INDUSTRIALS
Want more shares? Try these...
Chalice Mining Ltd. engages in the development of mineral projects. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-03-24. The firm is engaged in the exploration and evaluation of the Gonneville Nickel-Copper-PGE Project and the exploration of projects located in the West Yilgarn region of Western Australia. The Gonneville Platinum Group Element-Nickel-Copper-Cobalt (PGE-Ni-Cu-Co) is a development project located on Chalice-owned farmland, in Western Australia. Gonneville PGE-Ni-Cu-Co Project is located on Chalice-owned farmland over 70 kilometers north-east of Perth, Western Australia. Its projects include Julimar Nickel-Copper-PGE Exploration Project, Kings Nickel-Copper-PGE Exploration Project, Northam Resources Joint Venture Nickel-Copper-PGE Exploration Project, Barrabarra Nickel-Copper-PGE Exploration Project, South West Nickel-Copper-PGE Exploration Project, Narryer Nickel-Copper-PGE Exploration Project, Auralia Nickel-Copper-PGE Exploration Project, Warrego North Copper-Gold Exploration Project and Nulla South Gold Exploration Project.
🙌 Performance (5Yr p.a)
97.75%
📊 Share price
$1.18 AUD
⛏️ MINING
Charger Metals NL operates as a lithium and other base metals mining company. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2021-07-09. The firm is focused on two highly prospective lithium projects where proven systematic lithium exploration has generated several high priority drill-ready targets: Lake Johnston Lithium Project and Bynoe Lithium Project. The firm owns 100% of the Lake Johnston Lithium Project, which is located 450 kilometers (kms) east of Perth, Western Australia, in the central part of Yilgarn Lithium Province, which hosts the majority of Australia's Lithium Mineral Resources. The Bynoe Lithium Project covers approximately 63 square kilometers (km2), in a known lithium-enriched belt within the Litchfield Pegmatite Field, approximately 35 kms southwest of Darwin, Northern Territory, Australia. The Coates Nickel-copper-platinum group elements (Ni-Cu-PGE) Project is located around 65 kms east of Perth at Wundowie, Western Australia.
📊 Share price
$0.07 AUD
⛏️ MINING
Charter Hall Group engages in managing and investing in office, retail, and industrial properties. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-06-10. The firm operates a diverse portfolio of quality properties across core sectors, such as office, industrial and logistics, retail, and social infrastructure. The company operates through three segments: Property investments, Development investments, and Funds management. Property investments segment is comprised of investments in property funds. Development investments comprises investments in developments. Funds management comprises investment management services and property management services. The company owns and manages various properties across Australia, from landmark city offices and industrial and logistics facilities to local shopping centers and early learning centers. Its properties include 10 Shelley Street, 132-170 Andrews Rd, 6 Stewart Ave, 61 Mary Street, CoreWest Logistics Hub, Dandenong Distribution Centre, Edinburgh Parks Distribution Centre, No.1 Martin Place, and Pacific Square Shopping.
🙌 Performance (5Yr p.a)
5.59%
📊 Share price
$14.74 AUD
🏠 REAL ESTATE
🕊️ SOCIALLY AWARE
📈 HIGH PRICE GROWTH
Camplify Holdings Ltd. operates in the RV rental market. The Company’s platform delivers a seamless and transparent experience for consumers (potential RV hirers) to connect with RV owners and SMEs with a fleet of RVs. Its segments include Hire, Membership and Other. The firm has a global family of RV rental marketplace brands. The brands include Camplify, PaulCamper, MyWay and Rent a Tent. The firm provides a range of caravans, motorhomes, camper trailers and campervans for hire via the respective platforms. MyWay provides insurance solutions to the RV marketplace customers, and Rent a Tent provides accommodation services to festivals and events. The company operates in seven key markets, such as Australia, New Zealand, the United Kingdom, Spain, Germany, Netherlands and Austria. Its subsidiaries include Camplify Co (Australia) Pty Ltd, Camplify Co (NZ) Limited, and others.
📊 Share price
$0.75 AUD
🛤️ TRANSPORTATION INFRASTRUCTURE